Drug intelligence / Profile preview

OC125-PGA-CMA

Development stage: Preclinical
Lead developer: Massachusetts General Hospital
Modality: Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intraperitoneal

Overview

**OC125-PGA-CMA** is an experimental, CA-125-targeted photoimmunoconjugate developed for photodynamic treatment of ovarian cancer. It consists of the murine anti-CA-125 monoclonal antibody OC125 site-specifically coupled through a polyglutamic acid carrier to the chlorin photosensitizer chlorin e6-monoethylenediamine monoamide. Following intraperitoneal administration and illumination with activating light, the conjugate selectively accumulates in CA-125-positive ovarian tumor cells and the chlorin payload produces phototoxic oxidative damage. In a murine NIH:OVCAR3 ascites model, it achieved greater tumor photosensitizer concentrations than free photosensitizer and reduced viable tumor cells after photodynamic therapy, although single higher-dose light treatments produced substantial toxicity. ([nature.com](https://www.nature.com/articles/bjc1994330.pdf))

Other names: OC125-PGA-CMAOC-125-PGA-CMAOC 125-PGA-CMAOC125-PGA-CMA ICOC-125-PGA-CMA ICOC 125-PGA-CMA ICOC125-chlorin immunoconjugateOC-125-chlorin immunoconjugateOC 125-chlorin immunoconjugate

Targets

MUC16 (Mucin-16)

Beyond the preview

Go deeper on OC125-PGA-CMA.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OC125-PGA-CMA.

Explore the full profile